Summit Therapeutics (SMMT) – Investment Analysts’ Weekly Ratings Changes

Several analysts have recently updated their ratings and price targets for Summit Therapeutics (NASDAQ: SMMT):

• 10/27/2026 – Summit Therapeutics had its “market outperform” rating reaffirmed by Citigroup.
• 10/26/2026 – Summit Therapeutics had its “buy” rating reaffirmed by Jefferies Financial Group.
• 10/15/2026 – Summit Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 10/15/2026 – Summit Therapeutics had its “buy” rating reaffirmed by HC Wainwright.
• 10/5/2026 – Summit Therapeutics had its “market perform” rating reaffirmed by Sanford C. Bernstein.
• 10/1/2026 – Summit Therapeutics had its price target raised by Barclays from $18.00 to $20.00. They now have an “equal weight” rating on the stock.
• 9/30/2026 – Summit Therapeutics had its “neutral” rating reaffirmed by HC Wainwright.
• 9/29/2026 – Summit Therapeutics was given a new $41.00 price target by The Goldman Sachs Group. They now have a “buy” rating on the stock.
• 9/29/2026 – Summit Therapeutics was downgraded by Morgan Stanley to “outperform”.
• 9/29/2026 – Summit Therapeutics had its “buy” rating reaffirmed by Jefferies Financial Group. They now have a $30.00 price target on the stock.
• 9/25/2026 – Summit Therapeutics had its “buy” rating reaffirmed by Citigroup. They now have a $43.00 price target on the stock, up from $40.00.
• 9/23/2026 – Summit Therapeutics had its “neutral” rating reaffirmed by UBS Group.
• 9/23/2026 – Summit Therapeutics had its “neutral” rating reaffirmed by HC Wainwright.
• 9/22/2026 – Summit Therapeutics had its “overweight” rating reaffirmed by Cantor Fitzgerald.
• 9/9/2026 – Summit Therapeutics was given a new $25.00 price target by Summit Redstone.
• 9/8/2026 – Summit Therapeutics had its “buy” rating reaffirmed by UBS Group. They now have a $33.00 price target on the stock.
• 9/5/2026 – Summit Therapeutics was upgraded by Wall Street Zen from “sell” to “hold”.

Summit Therapeutics Trading Up 9.2%

SMMT traded up $1.37 on Tuesday, hitting $16.17. 2,722,998 shares of the company’s stock traded hands, compared to its average volume of 4,611,996. The company’s 50 day simple moving average is $16.09 and its 200-day simple moving average is $16.17. The firm has a market cap of $12.93 billion, a price-to-earnings ratio of -14.43 and a beta of -1.49. Summit Therapeutics PLC has a one year low of $12.07 and a one year high of $29.23.

Summit Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative medicines for the treatment of cancer. The company’s primary focus is oncology, with an emphasis on therapies designed to improve outcomes for patients with serious diseases.

Summit’s lead product candidate is ivonescimab, a bispecific antibody that is designed to combine immune checkpoint inhibition against PD-1 with anti-angiogenic activity targeting VEGF. The company is advancing ivonescimab in clinical studies for non-small cell lung cancer and is evaluating the therapy in combination with other cancer treatments and across additional treatment settings.

Summit holds exclusive rights to develop and commercialize ivonescimab in markets outside China through a licensing and collaboration agreement with Akeso, a China-based biopharmaceutical company.